DE69918541D1 - Verwendung von nmda antagonisten zur behandlung des reizkolons - Google Patents

Verwendung von nmda antagonisten zur behandlung des reizkolons

Info

Publication number
DE69918541D1
DE69918541D1 DE69918541T DE69918541T DE69918541D1 DE 69918541 D1 DE69918541 D1 DE 69918541D1 DE 69918541 T DE69918541 T DE 69918541T DE 69918541 T DE69918541 T DE 69918541T DE 69918541 D1 DE69918541 D1 DE 69918541D1
Authority
DE
Germany
Prior art keywords
nmda antagonists
treatment colon
colon
treatment
nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918541T
Other languages
English (en)
Other versions
DE69918541T2 (de
Inventor
Aziz Asghar
Luis Cabero
Andrew Dray
Anne King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9801494A external-priority patent/SE9801494D0/xx
Priority claimed from SE9803954A external-priority patent/SE9803954D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69918541D1 publication Critical patent/DE69918541D1/de
Application granted granted Critical
Publication of DE69918541T2 publication Critical patent/DE69918541T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69918541T 1998-04-28 1999-04-28 Verwendung von nmda antagonisten zur behandlung des reizkolons Expired - Fee Related DE69918541T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use
SE9801494 1998-04-28
SE9803954 1998-11-18
SE9803954A SE9803954D0 (sv) 1998-11-18 1998-11-18 Novel use
PCT/SE1999/000702 WO1999055323A1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome

Publications (2)

Publication Number Publication Date
DE69918541D1 true DE69918541D1 (de) 2004-08-12
DE69918541T2 DE69918541T2 (de) 2005-08-18

Family

ID=26663287

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918541T Expired - Fee Related DE69918541T2 (de) 1998-04-28 1999-04-28 Verwendung von nmda antagonisten zur behandlung des reizkolons

Country Status (21)

Country Link
EP (1) EP1073431B1 (de)
JP (1) JP2002512956A (de)
KR (1) KR100569777B1 (de)
CN (1) CN1200702C (de)
AR (1) AR016212A1 (de)
AT (1) ATE270545T1 (de)
AU (1) AU760783B2 (de)
BR (1) BR9909971A (de)
CA (1) CA2329328A1 (de)
DE (1) DE69918541T2 (de)
DK (1) DK1073431T3 (de)
ES (1) ES2221753T3 (de)
HK (1) HK1033876A1 (de)
IL (1) IL138919A0 (de)
MY (1) MY121063A (de)
NO (1) NO20005386L (de)
NZ (1) NZ507436A (de)
PT (1) PT1073431E (de)
SA (1) SA99200482B1 (de)
TW (1) TW570793B (de)
WO (1) WO1999055323A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119916A1 (en) * 2000-03-01 2003-06-26 David Fowler Treatment of functional gastrointestinal disorders
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
JP2003081872A (ja) * 2001-09-13 2003-03-19 Nippon Oruganon Kk 掻痒治療薬
EP1603544B1 (de) * 2003-03-14 2007-10-10 AGI Therapeutics Research Limited Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo¬2.2.1|heptan-2-amine
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
FR2865133B1 (fr) * 2004-01-19 2008-01-18 Rytek Compositions pour le traitement de pathologies digestives
CA3105834A1 (en) * 2018-07-06 2020-01-09 Algernon Pharmaceuticals Inc. Compounds for treatment of inflammatory bowel disease and methods thereof
KR102211282B1 (ko) 2019-11-20 2021-02-03 (주)파이브텍 데이터 라우팅 방법 및 이를 지원하는 스위치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition

Also Published As

Publication number Publication date
CN1307471A (zh) 2001-08-08
AU760783B2 (en) 2003-05-22
JP2002512956A (ja) 2002-05-08
EP1073431A1 (de) 2001-02-07
TW570793B (en) 2004-01-11
PT1073431E (pt) 2004-10-29
CA2329328A1 (en) 1999-11-04
HK1033876A1 (en) 2001-09-28
NO20005386D0 (no) 2000-10-26
ATE270545T1 (de) 2004-07-15
MY121063A (en) 2005-12-30
NZ507436A (en) 2003-09-26
WO1999055323A1 (en) 1999-11-04
AR016212A1 (es) 2001-06-20
SA99200482B1 (ar) 2006-06-27
DE69918541T2 (de) 2005-08-18
ES2221753T3 (es) 2005-01-01
CN1200702C (zh) 2005-05-11
DK1073431T3 (da) 2004-10-04
IL138919A0 (en) 2001-11-25
NO20005386L (no) 2000-10-26
EP1073431B1 (de) 2004-07-07
KR100569777B1 (ko) 2006-04-11
BR9909971A (pt) 2000-12-26
AU4302499A (en) 1999-11-16
KR20010043077A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE69922914D1 (de) Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE69519577D1 (de) Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE60038458D1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69905214T2 (de) Mittel zur Behandlung der Osteoporose
DE69918541D1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE433323T1 (de) Verwendung von erythropoietin zur behandlung von primärer hämochromatosen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee